Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 24, 2017
Pharmacy Choice - Pharmaceutical News - New Biosimilars Findings from N. Harbeck et al Outlined [Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian... - September 24, 2017

Pharmacy News Article

 9/12/17 - New Biosimilars Findings from N. Harbeck et al Outlined [Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian...

New Biosimilars Findings from N. Harbeck et al Outlined [Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials]

By a News Reporter-Staff News Editor at China Weekly News Investigators publish new report on Drugs and Therapies - Biosimilars. According to news reporting out of Munich, Germany, by VerticalNews editors, research stated, "This is a pooled subgroup analysis of Asian patients enrolled in two Phase III confirmatory studies comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in women receiving chemotherapy for breast cancer. Women were randomized to LA-EP2006 (n = 90) or reference (n = 84) pegfilgrastim (Neulasta , Amgen, Inc., CA, USA) for <= 6 cycles of TAC chemotherapy."

Our news journalists obtained a quote from the research, "Primary end point was duration of severe neutropenia during Cycle 1 (number of consecutive days with absolute neutrophil count <0.5 x 10(9)/l) with equivalence confirmed if 95% CIs were within a +/- 1-day margin. Mean duration of severe neutropenia (days) in Cycle 1 was 1.36 +/- 0.98 (LA-EP2006) versus 1.35 +/- 1.06 (reference) (difference 0.01 days; 95% CI: -0.30-0.32, indicating equivalence)."

According to the news editors, the research concluded: "LA-EP2006 showed similar clinical efficacy and safety compared with reference pegfilgrastim."

For more information on this research see: Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials. Future Oncology, 2017;13(16):1385-1393. Future Oncology can be contacted at: Future Medicine Ltd, Unitec House, 3RD Floor, 2 Albert Place, Finchley Central, London, N3 1QB, England.

Our news journalists report that additional information may be obtained by contacting N. Harbeck, Univ Munchen LMU, CCCLMU, Munich, Germany. Additional authors for this research include P. Gascon, C.M. Jones, A. Nixon, A. Krendyukov, R. Nakov, Y.H. Li and K. Blackwell.

Keywords for this news article include: Munich, Germany, Europe, Drugs and Therapies, Women's Health, Breast Cancer, Biosimilars, Oncology, Asia.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Sep 25: Management of Major Depressive Disorders
Sep 26: Vitamins, Minerals, and Electrolytes in Older Adults
Sep 27: Medication Use During Pregnancy & Lactation
Sep 28: An Integrative Approach to Managing Arthritis
Sep 29: Legal & Practical Issues in Compounding Pharmacy
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415